New Analyses from Amyloidosis and Hypertension Programs Presented at The American College of Cardiology (ACC) Scientific Sessions 2026

30 Mar, 2026 New Analyses from Amyloidosis and Hypertension Programs Presented at The American College of Cardiology (ACC) Scientific Sessions 2026

Analyses presented at ACC reinforce the totality of data for vutrisiran in patients with ATTR-CM including the impact on cardiovascular outcomes across a range of patient subgroups, including those with most advanced disease and diastolic dysfunction and on health-related quality of life. Real-world evidence also shows high treatment adherence with quarterly dosing.

A pooled safety analysis from the Phase 2 KARDIA studies demonstrate zilebesiran’s acceptable safety profile across a broad hypertension population, supporting continued investigation in the Phase 3 ZENITH cardiovascular outcomes trial.

Cuddy, et al. “Post Hoc Analysis of Diastolic Dysfunction in the HELIOS-B Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy”

DiDomenico, et al. “Polypharmacy and Potential for Drug–Drug Interactions Among Patients With ATTR-CM Initiating Tafamidis”

Hamatani, et al. “Impact of Vutrisiran on the Components of Quality of Life in Transthyretin Cardiomyopathy (ATTR-CM)”

Hefferman, et al. “Real-World Adherence and Persistence With Vutrisiran, an RNA Interference Therapeutic for the Treatment of Transthyretin Amyloidosis”

Witteles, et al. “Vutrisiran Reduces the Risk of Developing Advanced Disease and Demonstrates Benefit in Patients Who Do Develop Advanced Disease in ATTR-CM: Analysis From the HELIOS-B Study”

Desai, et al. “Pooled Safety Analysis of Zilebesiran, an Investigational Long-Acting RNA Interference, From Phase 2 Studies in Patients With Hypertension”